Adaptimmune Therapeutics (473A) Stock Overview
A commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
473A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Adaptimmune Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$0.58 |
| 52 Week Low | US$0.025 |
| Beta | 2.45 |
| 1 Month Change | 0% |
| 3 Month Change | 6.58% |
| 1 Year Change | -69.72% |
| 3 Year Change | -88.98% |
| 5 Year Change | -96.46% |
| Change since IPO | -98.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 473A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 3.2% |
| 1Y | -69.7% | -12.2% | 2.5% |
Return vs Industry: 473A underperformed the German Biotechs industry which returned -12.2% over the past year.
Return vs Market: 473A underperformed the German Market which returned 14.8% over the past year.
Price Volatility
| 473A volatility | |
|---|---|
| 473A Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 473A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 473A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 506 | Chris Hill | www.adaptimmune.com |
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
Adaptimmune Therapeutics plc Fundamentals Summary
| 473A fundamental statistics | |
|---|---|
| Market cap | €6.40m |
| Earnings (TTM) | -€146.31m |
| Revenue (TTM) | €56.10m |
Is 473A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 473A income statement (TTM) | |
|---|---|
| Revenue | US$65.09m |
| Cost of Revenue | US$128.69m |
| Gross Profit | -US$63.61m |
| Other Expenses | US$106.15m |
| Earnings | -US$169.76m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | -97.73% |
| Net Profit Margin | -260.82% |
| Debt/Equity Ratio | -36.2% |
How did 473A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/17 09:27 |
| End of Day Share Price | 2025/10/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adaptimmune Therapeutics plc is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | BofA Global Research |
| Mohit Bansal | Citigroup Inc |
| Reni Benjamin | Raymond James & Associates |